Adverum Biotechnologies (ADVM) Stock Forecast & Price Target

Compare

632 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ADVM Analyst Ratings

Moderate Buy

3 Buy

2 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Adverum

Biotechnologies

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ADVM Stock 12 Month Forecast

Average Price Target

$11.88

▲(328.88% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Adverum Biotechnologies in the last 3 months. The average price target is $11.88 with a high forecast of $30.00 and a low forecast of $2.50. The average price target represents a 328.88% change from the last price of $2.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.32,4.449230769230769,6.5784615384615375,8.707692307692307,10.836923076923076,12.966153846153846,15.095384615384614,17.224615384615383,19.353846153846153,21.483076923076922,23.61230769230769,25.74153846153846,27.870769230769227,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.32,3.0553846153846154,3.7907692307692304,4.526153846153846,5.2615384615384615,5.996923076923077,6.7323076923076925,7.4676923076923085,8.203076923076923,8.938461538461539,9.673846153846155,10.40923076923077,11.144615384615385,{"y":11.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.32,2.333846153846154,2.3476923076923075,2.3615384615384616,2.375384615384615,2.3892307692307693,2.403076923076923,2.416923076923077,2.4307692307692306,2.4446153846153846,2.4584615384615383,2.4723076923076923,2.4861538461538464,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.92,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$11.88

Lowest Price Target$2.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

$12

Buy

333.21%

Upside

Reiterated

08/14/25

Mizuho Securities Reaffirms Their Buy Rating on Adverum Biotechnologies (ADVM)

Dex Genotek

TR | OpenAI - 4o

$2.5

Hold

-9.75%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/13/25

Truist Financial Remains a Buy on Adverum Biotechnologies (ADVM)

Matthew Caufield

H.C. Wainwright

$30

Buy

983.03%

Upside

Reiterated

08/13/25

Promising Outlook for Adverum Biotechnologies' Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed

Lisa Walter

RBC Capital

Hold

8.30%

Upside

Reiterated

08/12/25

Adverum Biotechnologies (ADVM) Receives a Hold from RBC Capital

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

05/15/25

Promising Outlook for Adverum Biotechnologies: Buy Rating on ixo-vec's Advancements in Wet AMD Treatment

Francois Brisebois

Oppenheimer

$28

Buy

910.83%

Upside

Reiterated

11/05/24

Oppenheimer Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)

Keay Nakae

Chardan Capital

―

Buy

―

Reiterated

10/16/24

Promising Potential of ADAR RNA Editing Fuels Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

$12

Buy

333.21%

Upside

Reiterated

08/14/25

Mizuho Securities Reaffirms Their Buy Rating on Adverum Biotechnologies (ADVM)

Dex Genotek

TR | OpenAI - 4o

$2.5

Hold

-9.75%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/13/25

Truist Financial Remains a Buy on Adverum Biotechnologies (ADVM)

Matthew Caufield

H.C. Wainwright

$30

Buy

983.03%

Upside

Reiterated

08/13/25

Promising Outlook for Adverum Biotechnologies' Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed

Lisa Walter

RBC Capital

Hold

8.30%

Upside

Reiterated

08/12/25

Adverum Biotechnologies (ADVM) Receives a Hold from RBC Capital

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

05/15/25

Promising Outlook for Adverum Biotechnologies: Buy Rating on ixo-vec's Advancements in Wet AMD Treatment

Francois Brisebois

Oppenheimer

$28

Buy

910.83%

Upside

Reiterated

11/05/24

Oppenheimer Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)

Keay Nakae

Chardan Capital

―

Buy

―

Reiterated

10/16/24

Promising Potential of ADAR RNA Editing Fuels Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adverum Biotechnologies

1 Month

xxx

Success Rate

8/18 ratings generated profit

Average Return

+4.04%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of +4.04% per trade.

3 Months

xxx

Success Rate

5/15 ratings generated profit

Average Return

-2.41%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -2.41% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

4/15 ratings generated profit

Average Return

-43.20%

reiterated a buy rating 4 days ago

Copying Joon Lee's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -43.20% per trade.

2 Years

xxx

Success Rate

2/15 ratings generated profit

Average Return

-60.80%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -60.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ADVM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ADVM has received 4 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. ADVM average Analyst price target in the past 3 months is 11.88.

Each month's total comprises the sum of three months' worth of ratings.

ADVM Financial Forecast

ADVM Earnings Forecast

Next quarter’s earnings estimate for ADVM is -$1.74 with a range of -$2.45 to -$0.84. The previous quarter’s EPS was -$2.34. ADVM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year ADVM has Preformed in-line its overall industry.

ADVM Sales Forecast

Next quarter’s sales forecast for ADVM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ADVM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.42% of the time in the same period. In the last calendar year ADVM has Preformed in-line its overall industry.

ADVM Stock Forecast FAQ

What is ADVM’s average 12-month price target, according to analysts?

Based on analyst ratings, Adverum Biotechnologies’s 12-month average price target is 11.88.

What is ADVM’s upside potential, based on the analysts’ average price target?

Adverum Biotechnologies has 328.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ADVM a Buy, Sell or Hold?

Adverum Biotechnologies has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.

What is Adverum Biotechnologies’s price target?

The average price target for Adverum Biotechnologies is 11.88. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $2.50. The average price target represents 328.88% Increase from the current price of $2.77.

What do analysts say about Adverum Biotechnologies?

Adverum Biotechnologies’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ADVM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Adverum Biotechnologies (ADVM) Stock Forecast & Price Target

ADVM Analyst Ratings

ADVM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Adverum Biotechnologies

ADVM Analyst Recommendation Trends

ADVM Financial Forecast

ADVM Earnings Forecast

ADVM Sales Forecast

ADVM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts